GameChangers: COX-2 Inhibitors to Increase Effectiveness of Emergency Contraception

GameChangers: COX-2 Inhibitors to Increase Effectiveness of Emergency Contraception

Emergency contraception use has an effectiveness of about 70%. Join host, Geoff Wall, as he reviews new literature to see if COX-2 inhibition improves that rate.

THE GAMECHANGER: Emergency contraception (EC) is safe and effective but overall efficacy rates could be better. COX-2 inhibitors may enhance the effectiveness of EC but require multiday dosing.

Upon successful completion of this course, learners should be able to:
1. Describe the selection of the particular COX-2 medication used in this study
2. Discuss the implications of the COX-2 augmentation with patients

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: October 9, 2023
Planned Expiration Date: October 9, 2024

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-23-322-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.